OR WAIT null SECS
March 15, 2020
In January 2020, the agency finalized six clinical development and manufacturing guidance documents and drafted new guidance on what would qualify new gene therapies as orphan drugs.
March 02, 2020
Tackling process development early on can better optimize manufacturing processes for emerging therapies.
The growing interest in developing cell and gene therapies has prompted industry investment to grow manufacturing capacity.
The last year has seen intense investment activity into raising cell and gene therapy manufacturing capacity.
February 19, 2020
The 135,000 square foot facility will be constructed over 18 months and is expected to be operational in 2021.
February 10, 2020
New funding brings competitors, and a leading healthcare products distributor, into the standardization effort.
February 06, 2020
The new facility includes six classified environment rooms with space to expand.
Contract partners must help innovators, especially smaller and virtual companies, consider manufacturability as early as possible in development. This requires focusing on technical and operational performance, as well as cost.
February 02, 2020
Vein-to-vein programs are focusing on data access and traceability.
February 01, 2020
As cell and gene therapies become more prominent, industry is seeking the expertise and capabilities of outsourcing partners to ensure success.